Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sutherland

Showing results (871-880 of 999) with videos related to

Pageof 100
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2023
Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and LumefantrineDonelly A van Schalkwyk, Sade Pratt, Debbie Nolder, et al.
Antimicrobial Agents and Chemotherapy|December 10, 2014
Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strainsMonika Chugh, Christian Scheurer, Sibylle Sax, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Nature Communications|December 31, 2024
Genomic analysis of global Plasmodium vivax populations reveals insights into the evolution of drug resistanceGabrielle C Ngwana-Joseph, Jody E Phelan, Emilia Manko, et al.
British Journal of Haematology|October 4, 2005
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphomaRichard T Doocey, Cynthia L Toze, Joseph M Connors, et al.
British Journal of Haematology|May 18, 2006
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphomaKevin W Song, Michael J Barnett, Randy D Gascoyne, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2018
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted AnalysisWasithep Limvorapitak, Michael J Barnett, Donna E Hogge, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Pageof 100

Showing results (871-880 of 999) with videos related to

Sort By:
Pageof 100
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2023
Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and LumefantrineDonelly A van Schalkwyk, Sade Pratt, Debbie Nolder, et al.
Antimicrobial Agents and Chemotherapy|December 10, 2014
Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strainsMonika Chugh, Christian Scheurer, Sibylle Sax, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Nature Communications|December 31, 2024
Genomic analysis of global Plasmodium vivax populations reveals insights into the evolution of drug resistanceGabrielle C Ngwana-Joseph, Jody E Phelan, Emilia Manko, et al.
British Journal of Haematology|October 4, 2005
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphomaRichard T Doocey, Cynthia L Toze, Joseph M Connors, et al.
British Journal of Haematology|May 18, 2006
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphomaKevin W Song, Michael J Barnett, Randy D Gascoyne, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2018
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted AnalysisWasithep Limvorapitak, Michael J Barnett, Donna E Hogge, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Pageof 100